Investors

Currently, cancer patients who experience recurrence of disease face a challenging prognosis and limited new treatment options – especially in glioblastoma (brain cancer), colorectal, pancreatic, ovarian, and small cell lung cancers.

High toxicity levels in available marketed treatments can lead to their discontinuation, due to tolerability and/or quality of life issues.

Vivacitas’ lead program AR-67, is a lipophilic small molecule compound with a proprietary synthesis method developed to address especially hard-to-treat tumors and improve tolerability and patient comfort.

Novel technology

Using breakthrough technology to evolve current treatments and improve patient quality of life.

Advancing current treatment

AR-67 is a new generation of treatment, building on its current strengths and advancing it further.

Proprietary method

Our patented synthesis method has the potential to transform the current oncology treatment space.

Powerful technical expertise

Our expert team brings a scientific pedigree of vision and tenacity to push innovation forward.

Backed by clinical data

Preclinical, Phase I, and Phase II clinical data for AR-67 already shows promise for treatment of tough-to-treat cancers such as recurrent glioblastoma.

Patient-centric Focus

The patient is at the heart of everything we do and fuels our ambitions to accelerate innovation for scientific discovery.

Preclinical, Phase 1 & Phase II Trials Indicate:

  • Progression-Free Survival of 6 months or more
  • Overall Survival of 6 months or more
  • Safety/Toxicity superior to existing Camptothecins
  • Tolerability superior to Lomustine
AR-67 has the potential to deliver the efficacy of Camptothecins with significantly less gastrointestinal and hematological toxicity than Irinotecan. That could be a game changer for patients with gastrointestinal cancers.
Dr. Gerard Blobe, MD, PhD.Duke University School of Medicine.
AR–67 is a next generation camptothecin optimized for fewer side effects and blood-brain-barrier penetration. In glioblastoma patients treated with AR-67 on a clinical trial at our center, we saw encouraging outcomes and tumor shrinkage. AR-67 was extremely well tolerated. I believe AR-67 represents a novel approach in treating this devastating disease.
Dr. Jai Grewal, MD.NSPC Brain and Spine Surgery, NY

References

1. Novel silatecan displays high lipophilicity, improved blood stability and potent
anticancer activity. Bom D, et al J Med Chem 2000; 43:3970-3980

2. Silatecan DB-67 is a novel DNA Topo-1 targeted radiation sensitizer: Chen AY. Mol
Cancer Ther 2005; 4(2): 317-24.

3. Phase I study publication: Arnold SM, et al. Clin Cancer Res. 2010;6:673-680

4. Phase II study publication (abstract): Kumthekar P, et al. SNO 2019. Poster ACTR-40,
published in Neuro-Oncology(https://academic.oup.com/neuro-oncology)

5. Ubiquitin-dependent Destruction of Topoisomerase I Is
Stimulated by the Antitumor Drug Camptothecin*, Desai et al. The Journal of Biological Chemistry, Vol. 272, No. 39, Issue of September 26, pp. 24159–24164, 1997.  https://www.jbc.org

6. Metabolic Pathways of the Camptothecin Analog AR-67, Horn et al. Drug Metabolism and Disposition, Vol. 39, No. 4, 37390/3672838, 2011. https://dmd.aspetjournals.org